Monograph: |
OPIPRAMOL
DESCRIPTION
OPIPRAMOL HAS BEEN USED IN TRIALS STUDYING THE TREATMENT OF DEMENTIA, DEPRESSION, SCHIZOPHRENIA, ANXIETY DISORDERS, AND PSYCHOSOMATIC DISORDERS.
DRUG INTERACTION
(R)-WARFARIN THE RISK OR SEVERITY OF ADVERSE EFFECTS CAN BE INCREASED WHEN OPIPRAMOL IS COMBINED WITH (R)-WARFARIN.
(S)-WARFARIN THE RISK OR SEVERITY OF ADVERSE EFFECTS CAN BE INCREASED WHEN OPIPRAMOL IS COMBINED WITH (S)-WARFARIN.
1-(2-PHENYLETHYL)-4-PHENYL-4-ACETOXYPIPERIDINE THE METABOLISM OF OPIPRAMOL CAN BE DECREASED WHEN COMBINED WITH 1-(2-PHENYLETHYL)-4-PHENYL-4-ACETOXYPIPERIDINE.
1-BENZYLIMIDAZOLE THE RISK OR SEVERITY OF HYPERTENSION CAN BE INCREASED WHEN 1-BENZYLIMIDAZOLE IS COMBINED WITH OPIPRAMOL.
2,4-THIAZOLIDINEDIONE OPIPRAMOL MAY DECREASE THE HYPOGLYCEMIC ACTIVITIES OF 2,4-THIAZOLIDINEDIONE.
2,5-DIMETHOXY-4-ETHYLAMPHETAMINE THE THERAPEUTIC EFFICACY OF OPIPRAMOL CAN BE INCREASED WHEN USED IN COMBINATION WITH 2,5-DIMETHOXY-4-ETHYLAMPHETAMINE.
2,5-DIMETHOXY-4-ETHYLTHIOAMPHETAMINE THE THERAPEUTIC EFFICACY OF OPIPRAMOL CAN BE INCREASED WHEN USED IN COMBINATION WITH 2,5-DIMETHOXY-4-ETHYLTHIOAMPHETAMINE.
3,5-DIIODOTHYROPROPIONIC ACID THE RISK OR SEVERITY OF CARDIAC ARRHYTHMIA CAN BE INCREASED WHEN 3,5-DIIODOTHYROPROPIONIC ACID IS COMBINED WITH OPIPRAMOL.
3,5-DIIODOTYROSINE THE RISK OR SEVERITY OF CARDIAC ARRHYTHMIA CAN BE INCREASED WHEN 3,5-DIIODOTYROSINE IS COMBINED WITH OPIPRAMOL.
4-BROMO-2,5-DIMETHOXYAMPHETAMINE THE THERAPEUTIC EFFICACY OF OPIPRAMOL CAN BE INCREASED WHEN USED IN COMBINATION WITH 4-BROMO-2,5-DIMETHOXYAMPHETAMINE.
4-BROMO-2,5-DIMETHOXYPHENETHYLAMINE THE RISK OR SEVERITY OF HYPERTENSION CAN BE INCREASED WHEN OPIPRAMOL IS COMBINED WITH 4-BROMO-2,5-DIMETHOXYPHENETHYLAMINE.
4-HYDROXYCOUMARIN THE RISK OR SEVERITY OF ADVERSE EFFECTS CAN BE INCREASED WHEN OPIPRAMOL IS COMBINED WITH 4-HYDROXYCOUMARIN.
4-METHOXYAMPHETAMINE 4-METHOXYAMPHETAMINE MAY INCREASE THE VASOPRESSOR ACTIVITIES OF OPIPRAMOL.
5-METHOXY-N,N-DIMETHYLTRYPTAMINE THE RISK OR SEVERITY OF ADVERSE EFFECTS CAN BE INCREASED WHEN OPIPRAMOL IS COMBINED WITH 5-METHOXY-N,N-DIMETHYLTRYPTAMINE.
7-NITROINDAZOLE THE RISK OR SEVERITY OF ADVERSE EFFECTS CAN BE INCREASED WHEN 7-NITROINDAZOLE IS COMBINED WITH OPIPRAMOL.
7,8-DICHLORO-1,2,3,4-TETRAHYDROISOQUINOLINE 7,8-DICHLORO-1,2,3,4-TETRAHYDROISOQUINOLINE MAY INCREASE THE SEROTONERGIC ACTIVITIES OF OPIPRAMOL.
ABATACEPT THE METABOLISM OF OPIPRAMOL CAN BE INCREASED WHEN COMBINED WITH ABATACEPT.
ABEDITEROL THE RISK OR SEVERITY OF HYPERTENSION CAN BE INCREASED WHEN OPIPRAMOL IS COMBINED WITH ABEDITEROL.
ABIRATERONE THE METABOLISM OF OPIPRAMOL CAN BE DECREASED WHEN COMBINED WITH ABIRATERONE.
ACARBOSE OPIPRAMOL MAY DECREASE THE HYPOGLYCEMIC ACTIVITIES OF ACARBOSE.
ACEBUTOLOL THE METABOLISM OF ACEBUTOLOL CAN BE DECREASED WHEN COMBINED WITH OPIPRAMOL.
ACECLOFENAC THE RISK OR SEVERITY OF HYPERTENSION CAN BE INCREASED WHEN ACECLOFENAC IS COMBINED WITH OPIPRAMOL.
ACEMETACIN THE RISK OR SEVERITY OF HYPERTENSION CAN BE INCREASED WHEN OPIPRAMOL IS COMBINED WITH ACEMETACIN.
ACENOCOUMAROL THE RISK OR SEVERITY OF ADVERSE EFFECTS CAN BE INCREASED WHEN OPIPRAMOL IS COMBINED WITH ACENOCOUMAROL.
ACEPROMAZINE THE SERUM CONCENTRATION OF OPIPRAMOL CAN BE INCREASED WHEN IT IS COMBINED WITH ACEPROMAZINE.
ACEPROMETAZINE THE SERUM CONCENTRATION OF OPIPRAMOL CAN BE INCREASED WHEN IT IS COMBINED WITH ACEPROMETAZINE.
ACETAMINOPHEN THE METABOLISM OF OPIPRAMOL CAN BE DECREASED WHEN COMBINED WITH ACETAMINOPHEN.
ACETAZOLAMIDE THE RISK OR SEVERITY OF ADVERSE EFFECTS CAN BE INCREASED WHEN ACETAZOLAMIDE IS COMBINED WITH OPIPRAMOL.
ACETOHEXAMIDE OPIPRAMOL MAY DECREASE THE HYPOGLYCEMIC ACTIVITIES OF ACETOHEXAMIDE.
ACETOPHENAZINE THE SERUM CONCENTRATION OF OPIPRAMOL CAN BE INCREASED WHEN IT IS COMBINED WITH ACETOPHENAZINE.
ACETYLGLYCINAMIDE CHLORAL HYDRATE THE RISK OR SEVERITY OF ADVERSE EFFECTS CAN BE INCREASED WHEN OPIPRAMOL IS COMBINED WITH ACETYLGLYCINAMIDE CHLORAL HYDRATE.
ACETYLSALICYLIC ACID THE RISK OR SEVERITY OF HYPERTENSION CAN BE INCREASED WHEN ACETYLSALICYLIC ACID IS COMBINED WITH OPIPRAMOL.
ACLIDINIUM OPIPRAMOL MAY INCREASE THE CENTRAL NERVOUS SYSTEM DEPRESSANT (CNS DEPRESSANT) ACTIVITIES OF ACLIDINIUM.
ADALIMUMAB THE METABOLISM OF OPIPRAMOL CAN BE INCREASED WHEN COMBINED WITH ADALIMUMAB.
ADINAZOLAM THE RISK OR SEVERITY OF ADVERSE EFFECTS CAN BE INCREASED WHEN ADINAZOLAM IS COMBINED WITH OPIPRAMOL.
ADIPIPLON THE RISK OR SEVERITY OF ADVERSE EFFECTS CAN BE INCREASED WHEN ADIPIPLON IS COMBINED WITH OPIPRAMOL.
ADRAFINIL THE RISK OR SEVERITY OF HYPERTENSION CAN BE INCREASED WHEN OPIPRAMOL IS COMBINED WITH ADRAFINIL.
AFELIMOMAB THE METABOLISM OF OPIPRAMOL CAN BE INCREASED WHEN COMBINED WITH AFELIMOMAB.
AGMATINE THE RISK OR SEVERITY OF ADVERSE EFFECTS CAN BE INCREASED WHEN AGMATINE IS COMBINED WITH OPIPRAMOL.
AGOMELATINE THE RISK OR SEVERITY OF ADVERSE EFFECTS CAN BE INCREASED WHEN AGOMELATINE IS COMBINED WITH OPIPRAMOL.
AICA RIBONUCLEOTIDE OPIPRAMOL MAY DECREASE THE HYPOGLYCEMIC ACTIVITIES OF AICA RIBONUCLEOTIDE.
AJULEMIC ACID THE RISK OR SEVERITY OF ADVERSE EFFECTS CAN BE INCREASED WHEN AJULEMIC ACID IS COMBINED WITH OPIPRAMOL.
ALAPROCLATE THE RISK OR SEVERITY OF ADVERSE EFFECTS CAN BE INCREASED WHEN OPIPRAMOL IS COMBINED WITH ALAPROCLATE.
ALBIGLUTIDE OPIPRAMOL MAY DECREASE THE HYPOGLYCEMIC ACTIVITIES OF ALBIGLUTIDE.
ALCLOFENAC THE RISK OR SEVERITY OF HYPERTENSION CAN BE INCREASED WHEN OPIPRAMOL IS COMBINED WITH ALCLOFENAC.
ALCURONIUM THE RISK OR SEVERITY OF ADVERSE EFFECTS CAN BE INCREASED WHEN OPIPRAMOL IS COMBINED WITH ALCURONIUM.
ALFAXALONE THE RISK OR SEVERITY OF ADVERSE EFFECTS CAN BE INCREASED WHEN ALFAXALONE IS COMBINED WITH OPIPRAMOL.
ALFENTANIL THE RISK OR SEVERITY OF ADVERSE EFFECTS CAN BE INCREASED WHEN ALFENTANIL IS COMBINED WITH OPIPRAMOL.
ALIMEMAZINE THE SERUM CONCENTRATION OF OPIPRAMOL CAN BE INCREASED WHEN IT IS COMBINED WITH ALIMEMAZINE.
ALISKIREN OPIPRAMOL MAY DECREASE THE ANTIHYPERTENSIVE ACTIVITIES OF ALISKIREN.
|